Steroid hormones bind to their receptors and trans-activate target genes. Rapid non-genomic action of steroid hormones has been proposed in addition to the one at the genomic level. Estrogen has been described to activate c-Src kinase and this activation has been shown to be responsible for estrogen-dependent mitogenicity. A major substrate of c-Src kinase activity is the cytoskeletal protein p130Cas, originally identified in v-Src-transformed cells. We show that in the human breast carcinoma T47D cells, upon estrogen treatment, p130Cas rapidly and transiently associates with the estrogen receptor alpha in a multi-molecular complex containing the c-Src kinase and the p85 subunit of PI 3-kinase. Association of p130Cas with the estrogen receptor alpha occurs within 3 minutes of estrogen treatment and is dependent on c-Src kinase activation. Transient overexpression of p130Cas in T47D cells increases estrogen-dependent Src kinase and Erk1/2 MAPKs activities and accelerates their kinetics of stimulation. A similar effect was detected on estrogen-dependent cyclin D1 expression, suggesting a role for p130Cas in regulating estrogen-dependent cell cycle progression. Double-stranded small RNA interference (siRNA) by silencing endogenous p130Cas protein, was sufficient to inhibit estrogen-dependent Erk1/2 MAPKs activity and cyclin D1 induction, demonstrating the requirement of p130Cas in such events. Therefore, our data show that the adaptor protein p130Cas associates with the estrogen receptor transducing complex, regulating estrogen-dependent activation of c-Src kinase and downstream signaling pathways.

Download full-text PDF

Source
http://dx.doi.org/10.1242/jcs.01025DOI Listing

Publication Analysis

Top Keywords

c-src kinase
20
estrogen receptor
16
receptor alpha
12
p130cas
9
estrogen
8
steroid hormones
8
kinase activation
8
protein p130cas
8
t47d cells
8
estrogen treatment
8

Similar Publications

Discovery of anti-tumor small molecule lead compounds targeting the SH3 domain of c-Src protein through virtual screening and biological evaluation.

Arch Biochem Biophys

February 2025

Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China; The Second Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China. Electronic address:

Article Synopsis
  • c-Src is a non-receptor tyrosine kinase involved in important cellular functions like growth and movement, and its dysfunction is linked to cancer progression.
  • Current treatments mainly target its kinase domain, but drug resistance limits their effectiveness.
  • This study discovered three compounds that effectively bind to the SH3 domain of c-Src and inhibit its activity, suggesting new potential anti-cancer drugs that could overcome resistance issues.
View Article and Find Full Text PDF

C-terminal Src kinase (Csk) targets Src family kinases (SFKs) and thereby inactivates them. We have previously shown that Csk binds to phosphorylated tyrosine 685 of VE-cadherin, an adhesion molecule of major importance for the regulation of endothelial junctions. This tyrosine residue is an SFK target, and its mutation (VE-cadherin-Y685F) inhibits the induction of vascular permeability in various inflammation models.

View Article and Find Full Text PDF

Recent advances of small-molecule c-Src inhibitors for potential therapeutic utilities.

Bioorg Chem

October 2023

School of Pharmacy, Key Laboratory of Elemene Class Anticancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China. Electronic address:

Article Synopsis
  • Proto-oncogene tyrosine-protein kinase Src (c-Src) is a key player in cell processes like division and survival, affecting both healthy and cancerous cells through various signaling pathways.
  • There is a strong link between c-Src and bone-related diseases, such as osteoporosis, because of its role in osteoclasts and inflammation.
  • Recent efforts have led to the development of c-Src inhibitors, with a review highlighting advances in their mechanisms, drug discovery, combination therapies, and ongoing clinical research to inspire further innovation in treatment options.
View Article and Find Full Text PDF

Focal Adhesion Kinase (FAK) and c-Src Dependent Signal Transduction in Cell Adhesion.

Discov Med

October 2024

Laboratory of Human Anatomy and Cell Biology, Faculty of Health Sciences, Tsukuba University of Technology, 305-8521 Tsukuba, Japan.

This review predominantly acquaints the role of focal adhesion kinase (FAK) and cellular-Src (c-Src) in cell adhesion. Cell adhesion is a crucial phenomenon that causes the cells to interact with the extracellular matrix (ECM) or with each other. There are different proteins involved in cell adhesion including cell adhesion molecules (CAMs)/receptors that are present on the cell surface and various cytoplasmic proteins.

View Article and Find Full Text PDF

Structural Basis for Long Residence Time c-Src Antagonist: Insights from Molecular Dynamics Simulations.

Int J Mol Sci

September 2024

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, China.

Article Synopsis
  • c-Src plays a crucial role in various cancer signaling pathways and is a key target for cancer treatment.
  • Research indicates that extending the residence time of drugs can improve their effectiveness, leading to the development of c-Src antagonists with longer residence times.
  • The study utilized molecular dynamics simulations to analyze the binding behavior of different antagonists, identifying a new compound, DFOGS, that enhances binding stability by replacing an unstable amide group, which could lead to better therapeutic outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!